Abstract: The present invention relates to a plant growth regulator of elevating anti-stress ability and use thereof. The plant growth regulator, which is consisted of Lactobacillus fermenting culture solution, has excellent thermostability and safety without any side effect, significantly elevating ability against biotic and abiotic stresses. Therefore, the Lactobacillus fermenting culture solution can be applied as the plant growth regulator or a use in preparation of a composition for elevating anti-stress ability of a plant.

Abstract: The present invention relates to a topical composition of facilitating wound healing and reducing scars, which includes an inactivated culture of Lactobacillus species as an effective ingredient and can significantly facilitate wound healing as well as reducing scars, thereby can be applied to a method of facilitating wound healing and reducing scars.

Abstract: The present invention provides a use for probiotic preparing skin care composition, wherein the probiotic comprises Lactobacillus plantarum (GMNL-6) with preservation number of BCRC 910777 or CCTCC M 2017765. The composition may be externally-coating drug, pharmaceuticals for external use, care products for external use or cosmetics, and may achieve the effects of improving the skin conditions or aesthetic appearance by promoting secretion of collagen or expression of ceramide synthase.

Abstract: The present invention is related to a Lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of Lactobacillus paracasei strain GMNL-32, L. reuteri strain GMNL-89 or L. reuteri strain GMNL-263, and a pharmaceutical carrier, for treating syndromes and related complications of the autoimmune diseases.

Abstract: The present invention provides a composition for preventing stroke and ameliorating the severity of stroke and comprises an effective dose of Lactobacillus reuteri GMNL-89 and Lactobacillus paracasei GMNL-133; the accession number of Lactobacillus reuteri GMNL-89 is CCTCC M207154 and the accession number of Lactobacillus paracasei GMNL-133 is CCTCC M2011331. The composition can be taken as a dietary supplement and be given continuously after a stroke, and said composition has the effects of ameliorating cerebral infarction, motor function, and intestinal microbiota after a stroke.

Abstract: The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.

Abstract: The present invention relates to a probiotic composition for preventing, improving or alleviating pancreatic cancer and a method for preventing, improving or alleviating the pancreatic cancer and its complications using the probiotic composition. The probiotic composition, which is consisted of specific strains and specific ratio of Lactobacillus paracasei to Lactobacillus reuteri, can significantly improve or alleviate various symptomatic indicators and severity of pancreatic cancer, thereby being applied on a method for preventing, improving or alleviating the pancreatic cancer and its complications using an oral composition including the Lactobacillus strains.

Abstract: Use of Lactobacillus paracasei for preparing for a combination for alleviating axillary osmidrosis is provided in the present invention, wherein Lactobacillus paracasei refers in particular to Lactobacillus paracasei GMNL-653, featuring abilities of aggregating and inhibiting pathogens of axillary osmidrosis for alleviation of armpit odors and presented as a topical medication or a combination of cosmetics in which fragrance is added.

Abstract: A composition is used for prevention or treatment of bacterial vaginosis (BV) and regulation of vaginal immunity and said composition with effective amount is selected from the groups comprising Lactobacillus rhamnosus GMNL-680 and Lactobacillus plantarum GMNL-682; the composition of the present invention is used to prevent and treat bacterial vaginosis by inhibition of the growth of pathogens and regulation of the expression of immunoregulators and is prepared in the forms of pharmaceutical compositions, food or other combinations thereof.

Abstract: The present invention is related to a Lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of Lactobacillus paracasei strain GMNL-32, L. reuteri strain GMNL-89 or L. reuteri strain GMNL-263, and a pharmaceutical carrier, for treating syndromes and related complications of the autoimmune diseases.

Abstract: An isolated Lactobacillus paracasei strain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolated Lactobacillus paracasei strain GMNL-133 is used for preparing a composition for use in the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of the Lactobacillus paracasei strain GMNL-133 is also disclosed.

Abstract: An isolated Lactobacillus paracasei strain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolated Lactobacillus paracasei strain GMNL-133 is used for preparing a composition for use in the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of the Lactobacillus paracasei strain GMNL-133 is also disclosed.

Abstract: A use of probiotic strain GM-080 in treating cardiac inflammation and apoptosis is disclosed. The probiotic strain GM-080 such as Lactobacillus paracasei strain GM-080 (accession No. CCTCC M 204012) is utilized to produce a composition for treating cardiac inflammation and apoptosis in an effective dose.

Abstract: Disclosed herein are two Lactobacillus isolates having anti-inflammatory activities and beneficial probiotic properties, i.e., Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The two Lactobacillus isolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.

Abstract: A bottle cap includes a cap seat and a cap. The cap seat has a receiving space confined by an inner tubular wall and a bottom wall. The cap is disposed within the inner tubular wall, and has a top panel and a tubular cutter body. The tubular cutter body has a beveled bottom open end that has a cutting end and a pushing end. When the top panel is pressed, the cutting end cuts the bottom wall, and the pushing end pushes a portion of the bottom wall so that the bottom wall moves away from the cutting end. Preferably, the bottom wall and the inner tubular wall are formed as one piece.

Abstract: Disclosed herein are two Lactobacillus isolates having anti-inflammatory activities and beneficial probiotic properties, i.e., Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The two Lactobacillus isolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.